Showing results (601-610 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 4, 2010
3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expressionGleice da Graça Rocha, Marisol Simões, Rodrigo Rodrigues Oliveira, et al.
Investigational New Drugs|September 25, 2010
Perirenal hematoma associated with bevacizumab treatmentHidetoshi Hayashi, Isamu Okamoto, Kazuhiko Nakagawa
Investigational New Drugs|October 5, 2010
Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agentsWen-Tai Li, Der-Ren Hwang, Jen-Shin Song, et al.
Investigational New Drugs|July 21, 2010
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKTChristopher R Garrett, Domenico Coppola, Robert M Wenham, et al.
Investigational New Drugs|July 8, 2010
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort studyPatricia Lorusso, Anthony F Shields, Shirish Gadgeel, et al.
Investigational New Drugs|August 3, 2010
YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathwayChin-Chuan Hung, Horng-Huei Liou
Investigational New Drugs|August 4, 2010
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignanciesElisabeth I Heath, Patricia Lorusso, Suresh S Ramalingam, et al.
Investigational New Drugs|July 10, 2010
Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugsNicolas Penel, Antoine Adenis, Stéphanie Clisant, et al.
Investigational New Drugs|June 23, 2010
Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitterMaryline Gardette, Janine Papon, Mathilde Bonnet, et al.
Investigational New Drugs|June 25, 2010
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinomaManish A Shah, Derek G Power, Hedy L Kindler, et al.
Pageof 372